JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 2002; 40:1339-1346
© 2002 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Genda, S.
Right arrow Articles by Shimamoto, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Genda, S.
Right arrow Articles by Shimamoto, K.

CLINICAL STUDY

KATP channel opening is an endogenous mechanism of protection against the no-reflow phenomenon but its function is compromised by hypercholesterolemia

Satoshi Genda, MD*, Tetsuji Miura, MD, PhD, FACC*,*, Takayuki Miki, MD, PhD*, Yoshihiko Ichikawa, MD* and Kazuaki Shimamoto, MD, PhD*

* Second Department of Internal Medicine, Sapporo Medical University, Sapporo, Japan

Manuscript received October 4, 2001; revised manuscript received May 7, 2002, accepted June 27, 2002.

* Reprint requests and correspondence: Dr. Tetsuji Miura, Second Department of Internal Medicine, Sapporo Medical University School of Medicine, South-1 West-16, Chuo-ku, Sapporo 060-8543 Japan.
miura{at}sapmed.ac.jp

OBJECTIVES: This study aimed to clarify the role of adenosine triphosphate-sensitive K+ (KATP) channels in the no-reflow phenomenon and in its extension by hypercholesterolemia.

BACKGROUND: The no-reflow phenomenon is an important target of therapy in patients with acute myocardial infarction, but its mechanism remains unclear.

METHODS: The left circumflex coronary artery was occluded for 30 or 60 min and reperfused in rabbit hearts in situ. The no-reflow zone, area at risk, and infarct size were determined by thioflavin-S, Evans blue, and tetrazolium staining, respectively. No-reflow zone size was expressed as a percentage of infarct size (%NR/IS). Hypercholesterolemia was induced by two weeks of cholesterol-enriched diet.

RESULTS: A KATP channel blocker, glibenclamide (0.3 mg/kg), increased %NR/IS after 30-min ischemia/90-min reperfusion from 33.6 ± 1.9% to 45.9 ± 1.6% and %NR/IS after 60-min ischemia/90-min reperfusion from 32.8 ± 3.4% to 46.1 ± 1.7%. However, NG-monomethyl-L-arginine (L-NMMA), a nitric oxide (NO) synthase inhibitor, and nicorandil, a hybrid of KATP channel opener and nitrate, failed to significantly modify %NR/IS. Hypercholesterolemia increased %NR/IS to 61.6 ± 0.6%, which was not further enlarged by glibenclamide, and delayed infarct healing during the subsequent five days of reperfusion. These effects of hypercholesterolemia were significantly suppressed by nicorandil. Neither glibenclamide, L-NMMA, nicorandil, nor hypercholesterolemia modified infarct size.

CONCLUSIONS: The KATP channel activation, but not NO, is a major mechanism of protection against microvascular injury, causing the no-reflow phenomenon in the heart. Suppression of KATP channel opening may underlie the hypercholesterolemia-induced extension of no-reflow, which delays infarct healing.

Abbreviations and Acronyms
  ANOVA
  analysis of variance
  GPTX
  pertussis toxin-sensitive G protein
  %IS/AR
  infarct size as a percentage of area at risk
  IV
  intravenous
  KATP channel
  adenosine triphosphate-sensitive K+ channel
  KCa channel
  Ca2+-activated K+ channel
  LDL-C
  low density lipoprotein-cholesterol
  L-NMMA
  NG-monomethyl-L-arginine
  NO
  nitric oxide
  NOS
  nitric oxide synthase
  %NR/IS
  no-reflow zone size as a percentage of infarct size
  %OZ/IS
  volume of organized infarct as a percentage of whole infarct size
  TC
  total cholesterol
  TG
  triglycerides




This article has been cited by other articles:


Home page
PerfusionHome page
J. Zhao, Y. Yang, W. Pei, Y. Sun, M Zhai, Y. Liu, and R. Gao
Carvedilol reduces myocardial no-reflow by decreasing endothelin-1 via activation of the ATP-sensitive K+ channel
Perfusion, March 1, 2008; 23(2): 111 - 115.
[Abstract] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. L. Hale, A. Mehra, J. Leeka, and R. A. Kloner
Postconditioning fails to improve no reflow or alter infarct size in an open-chest rabbit model of myocardial ischemia-reperfusion
Am J Physiol Heart Circ Physiol, January 1, 2008; 294(1): H421 - H425.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
T. Reffemann and R. A. Kloner
Microvascular Alterations After Temporary Coronary Artery Occlusion: The No-Reflow Phenomenon
Journal of Cardiovascular Pharmacology and Therapeutics, July 1, 2004; 9(3): 163 - 172.
[Abstract] [PDF]


Home page
HeartHome page
L Galiuto
Optimal therapeutic strategies in the setting of post-infarct no reflow: the need for a pathogenetic classification
Heart, February 1, 2004; 90(2): 123 - 125.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. A. Brady and A. Jovanovic
The sulfonylurea controversy: Much ado about nothing or cause for concern?
J. Am. Coll. Cardiol., September 17, 2003; 42(6): 1022 - 1025.
[Full Text] [PDF]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2002 by the American College of Cardiology Foundation.